Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is Catalent (CTLT) Stock a Good Buy During Covid-19 Uncertainty?

Artisan Mid Cap Fund recently released its Q1 2020 Investor Letter, a copy of which you can download below. The fund posted a return of -11.55% for the quarter (investor class), outperforming their benchmark, the Russell Midcap Index which returned -27.07% in the same quarter. You should check out Artisan Mid Cap Fund’s top 5 stock picks which helped them beat the market by nearly 16 percentage points. There weren’t a lot of funds who could deliver these kinds of returns without shorting the market or using aggressive put options.

In the said letter, Artisan Mid Cap Fund highlighted a few stocks and Catalent Inc. (NYSE:CTLT) is one of them. Catalent is a global provider of delivery technologies and development solutions for biologics, drugs,  and consumer health products. Year-to-date, CTLT stock gained 30.0% and on May 11th it had a closing price of $73.21. Its market cap is of $11.3 billion. Here is what Artisan Mid Cap Fund said:

“Catalent is one of the largest contract manufacturing suppliers to the pharmaceuticals industry. The company recently announced its acquisition of MaSTherCell Global, a cell- and gene-therapy contract development and manufacturing organization (CDMO). We believe the acquisition builds upon the company’s capabilities as a leading CDMO for biopharma companies. Gene therapies may finally be ready to emerge as valuable treatment options for patients with certain serious conditions, in our view, and developers of these medicines will require significant help from CDMOs. Shares came under pressure during the market selloff, in part due to concerns that their business supplying clinical trial supplies could be impacted by near-term clinical trial delays. With a longer time horizon, we viewed the share price dislocation as an opportunity to add to our position.”

In Q4 2019, the number of bullish hedge fund positions on CTLT stock decreased by about 28% from the previous quarter (see the chart here), so a number of other hedge fund managers don’t seem to agree with CTLT’s upside potential.

Disclosure: None. This article is originally published at Insider Monkey.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.